View Exam | PowerPak

1. When considering the level of value in guidelines and performance measures, the ACC/AHA set a High Value of better outcomes an ICER <_____ per quality adjusted life year (QALY) gained.

A. $25,000 B. $50,000 C. $75,000 D. $100,000

2. Which of the following formulas is used to calculate the Number Needed to Treat for Benefit?

A. 1/absolute risk reduction B. 1/ absolute risk increase C. absolute risk reduction/ absolute risk increase

3. In considering the use of DOACs for treatment of DVT/PE, which of the following is NOT true:

A. Shorter duration of therapy compared to management od atrial fibrillation B. Less major bleeding C. Higher rates of clinically relevant non-major bleeding D. Lower initial costs

4. In their review based on the COMPASS trial, ICER found that the cost of rivaroxaban per QALY gained was:

A. $20,000 B. $36,000 C. $50,000 D. $61,000

5. Which of the following is NOT in the ABCDEF Pharmacist Checklist for DOAC Management?

A. Adherence assessment and counseling B. BMI assessment C. Creatinine clearance D. Drug interaction assessment and education E. Examination F. Final assessment and plan

6. You have a patient who was just prescribed dual antiplatelet or anticoagulant therapy, and the patient had been treated for h. pylori a year ago. What would be your recommendation for use of prophylactic proton pump inhibitor?

A. I would recommend B. I would not recommend C. Wait one month and check for symptoms of GI bleeding before prescribing

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. When considering the level of value in guidelines and performance measures, the ACC/AHA set a High Value of better outcomes an ICER <_____ per quality adjusted life year (QALY) gained.

2. Which of the following formulas is used to calculate the Number Needed to Treat for Benefit?

3. In considering the use of DOACs for treatment of DVT/PE, which of the following is NOT true:

4. In their review based on the COMPASS trial, ICER found that the cost of rivaroxaban per QALY gained was:

5. Which of the following is NOT in the ABCDEF Pharmacist Checklist for DOAC Management?

6. You have a patient who was just prescribed dual antiplatelet or anticoagulant therapy, and the patient had been treated for h. pylori a year ago. What would be your recommendation for use of prophylactic proton pump inhibitor?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. When considering the level of value in guidelines and performance measures, the ACC/AHA set a High Value of better outcomes an ICER <_____ per quality adjusted life year (QALY) gained.

2. Which of the following formulas is used to calculate the Number Needed to Treat for Benefit?

3. In considering the use of DOACs for treatment of DVT/PE, which of the following is NOT true:

4. In their review based on the COMPASS trial, ICER found that the cost of rivaroxaban per QALY gained was:

5. Which of the following is NOT in the ABCDEF Pharmacist Checklist for DOAC Management?

6. You have a patient who was just prescribed dual antiplatelet or anticoagulant therapy, and the patient had been treated for h. pylori a year ago. What would be your recommendation for use of prophylactic proton pump inhibitor?

« Return to Activity

Customers who Purchased
this Activity also Purchased